Anal adenocarcinoma: resection best within 6 months of CRT

  • Lewis GD & al.
  • Ann Surg Oncol
  • 04/02/2019

  • Jim Kling
  • Univadis Clinical Summaries
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Patients with anal adenocarcinoma (AA) who undergo abdominoperineal resection (APR) have better survival if the surgery occurs within 6 months of receiving chemoradiotherapy (CRT) compared with a longer interval.

Why this matters

  • AA is a rare cancer, and there are no evidence-based treatment guidelines for it. This is the largest observational study of the condition to date.

Study design

  • Retrospective analysis of 24,461 patients (95.2% squamous cell carcinoma [AS]; 4.8% AA).
  • Funding: None disclosed.

Key results

  • Median OS was lower in AA vs AS (72.5 vs 143.8 months; P<.001>
  • 96.2% of patients with AA were treated with APR within 6 months of CRT.
  • Patients with AA who underwent APR within 6 months of CRT had a longer median survival than those who had APR ≥6 months after CRT (88.3 vs 58.1 months; P<.001>
  • The

Limitations

  • Retrospective analysis.